Stock CYBN CYBIN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Cybin Inc. Stock

Equities

CYBN

CA23256X1006

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 10:29:31 2024-05-09 am EDT 		5-day change 1st Jan Change
0.365 USD -1.35% Intraday chart for Cybin Inc. +3.94% -11.27%
May. 06 Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline CI
Apr. 17 Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * - Sales 2025 * - Capitalization 386M 281M
Net income 2024 * -74M -53.87M Net income 2025 * -70M -50.96M EV / Sales 2024 * -
Net cash position 2024 * 170M 124M Net cash position 2025 * 126M 91.58M EV / Sales 2025 * -
P/E ratio 2024 *
-2.15 x
P/E ratio 2025 *
-3.69 x
Employees 50
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.34%
More Fundamentals * Assessed data

Chart Cybin Inc.

Dynamic Chart

Latest news about Cybin Inc.

Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline CI
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment MT
Cybin Inc. announced that it has received $150 million in funding from a group of investors CI
Sector Update: Health Care Stocks Softer Friday Afternoon MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder MT
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder CI
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial MT
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design CI
Sector Update: Health Care Stocks Ease Wednesday Afternoon MT
Cybin Says Depression Drug Granted Breakthrough Designation by FDA; Raises $150 Million in Private Placement; Shares Jump MT
Transcript : Cybin Inc. - Special Call
Cybin Inc. Receives FDA Breakthrough Therapy Designation for Its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder CI
Cybin Inc. announced that it expects to receive $150 million in funding CI
Cybin Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
More news

Latest transcript on Cybin Inc.

Logo Cybin Inc.
Cybin Inc. - Special Call
More transcripts

Analyst Recommendations on Cybin Inc.

HC Wainwright Adjusts Cybin Price Target to $5 From $10, Maintains Buy Rating MT
Oppenheimer Adjusts Cybin Price Target to $4 From $4.50, Maintains Outperform Rating MT
Canaccord Genuity Adjusts Price Target on Cybin to $5 From $6, Maintains Buy Rating MT
Stifel Nicolaus Adjusts Cybin's Price Target to $1.13 From $1.10, Maintains Speculative Buy Rating MT
Canaccord Genuity Trims Price Target on Cybin to $6 From $7, Maintains Buy Rating MT
More recommendations

Press releases Cybin Inc.

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones AQ
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones  BU
Cybin to Participate at the 27th Annual Milken Institute Global Conference BU
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry BU
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder BU
More press releases

News in other languages on Cybin Inc.

Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3
Cybin reçoit la désignation de thérapie innovante de la FDA pour sa molécule psychédélique CYB003 et annonce des données de durabilité positives à quatre mois pour le traitement du trouble dépressif majeur
Annonce d’un placement privé sursouscrit de 150 millions USD
Cybin erhält von der FDA den Status eines Therapiedurchbruchs für sein neuartiges psychedelisches Molekül CYB003 und gibt positive Daten zur viermonatigen Dauerhaftigkeit bei schwerer depressiver Störung bekannt
More news

Quotes and Performance

1 day-1.35%
1 week+5.71%
Current month+5.71%
1 month-14.94%
3 months+11.45%
6 months-28.28%
Current year-9.76%
More quotes

Highs and lows

1 week
0.35
Extreme 0.3451
0.38
1 month
0.34
Extreme 0.337
0.42
Current year
0.28
Extreme 0.2831
0.52
1 year
0.21
Extreme 0.21
0.74
3 years
0.21
Extreme 0.21
3.38
5 years
0.21
Extreme 0.21
3.38
10 years
0.21
Extreme 0.21
3.38
More quotes

Managers and Directors - Cybin Inc.

Managers TitleAgeSince
Douglas Drysdale CEO
 Chief Executive Officer 54 20-07-31
Paul Glavine FOU
 Founder 35 16-10-12
Eric So FOU
 Founder 49 16-10-12
Members of the board TitleAgeSince
Eric So FOU
 Founder 49 16-10-12
Mark Lawson BRD
 Director/Board Member 52 20-11-04
Grant Froese BRD
 Director/Board Member 62 20-11-04
More insiders

Quotes

Date Price Change Volume
24-05-09 0.3648 -1.41% 224 400
24-05-08 0.37 +0.27% 1,488,195
24-05-07 0.369 +0.27% 2,077,291
24-05-06 0.368 +5.14% 4,895,337
24-05-03 0.35 0.00% 2,756,904

Delayed Quote Nyse, May 08, 2024 at 04:00 pm EDT

More quotes

Company Profile

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
Sector
Biotechnology & Medical Research
Calendar
2024-06-18 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
0.5077 CAD
Average target price
6.075 CAD
Spread / Average Target
+1,096.46%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
CYBIN INC. Stock Cybin Inc.
-9.76% 281M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.93% 108B
ARGENX SE Stock argenx SE
+7.02% 23.46B
BIONTECH SE Stock BioNTech SE
-14.60% 21.72B
GENMAB A/S Stock Genmab A/S
-7.05% 18.64B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.55% 17.45B
BEIGENE, LTD. Stock BeiGene, Ltd.
-8.83% 17.19B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.51% 13.99B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.49% 12.53B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+329.39% 8.81B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. CYBN Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW